Editas Medicine, Inc.

NasdaqGS:EDIT 株式レポート

時価総額：US$240.8m

Editas Medicine マネジメント

マネジメント 基準チェック /24

Editas Medicineの CEO はGilmore O’Neillで、 Jun2022年に任命され、 の在任期間は 3.92年です。 の年間総報酬は$ 2.35Mで、 29.2%給与と70.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.17%を直接所有しており、その価値は$ 403.88K 。経営陣と取締役会の平均在任期間はそれぞれ1.7年と7.3年です。

主要情報

Gilmore O’Neill

最高経営責任者

US$2.4m

報酬総額

CEO給与比率29.17%
CEO在任期間3.9yrs
CEOの所有権0.2%
経営陣の平均在職期間1.7yrs
取締役会の平均在任期間7.3yrs

経営陣の近況

Recent updates

分析記事 • May 14

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...
分析記事 • May 08

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

The first-quarter results for Editas Medicine, Inc. ( NASDAQ:EDIT ) were released last week, making it a good time to...
分析記事 • Nov 13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

A week ago, Editas Medicine, Inc. ( NASDAQ:EDIT ) came out with a strong set of quarterly numbers that could...
分析記事 • Nov 05

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have retraced a considerable 29% in the last month, reversing a fair...
分析記事 • Nov 02

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Summary Gene editing seems like a great idea: instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as CRISPR. I previously covered two companies, CRISPR Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a CRISPR licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly. With two strikes against it, EDIT is back in the batter’s box. And unlike peers that attack small-population problems, EDIT is swinging at the mass market, high LDL ("bad") cholesterol. It’s way too early to gauge potential success. But given a big target market, pioneering in-the-body editing, and a beaten-down stock, EDIT's reward-risk balance tilts toward ‘Buy.’. Read the full article on Seeking Alpha
分析記事 • Sep 09

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have been powering on, with a gain of 26...
分析記事 • Jul 22

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have continued their recent momentum with a 42% gain in the last month...
分析記事 • Jun 17

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 21

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
分析記事 • Mar 30

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has softened a substantial 35% over the previous 30 days, handing...
分析記事 • Mar 13

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 17

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Summary Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided. Both companies face high risks, including potential off-target effects and market volatility, requiring cautious investment and risk mitigation strategies. Read the full article on Seeking Alpha
分析記事 • Nov 20

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
分析記事 • Nov 06

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • Sep 26

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 25

Editas Medicine: A Risk/Reward Worth Considering

Summary Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks. EDIT's current valuation and potential market growth present an attractive investment opportunity, with a speculative yet promising outlook for long-term gains. Read the full article on Seeking Alpha
分析記事 • Aug 23

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
分析記事 • Aug 10

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest second-quarter, and things did...
分析記事 • May 12

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest quarterly, and things did not...
分析記事 • Apr 23

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

To the annoyance of some shareholders, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares are down a considerable 25% in the...
分析記事 • Mar 09

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Those holding Editas Medicine, Inc. ( NASDAQ:EDIT ) shares would be relieved that the share price has rebounded 28% in...
Seeking Alpha • Feb 28

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Summary Results from the Editas Medicine, Inc. phase 1/2 studies using reni-cel for the treatment of patients with Sickle-Cell Disease and Transfusion dependent thalassemia are expected in mid-2024 and end of 2024. The global Sickle-Cell Disease treatment market size is expected to be worth $7.79 billion by 2032. The global thalassemia treatment market is expected to reach $1.5 billion by end of 2031. Editas Medicine can overcome competition with owning several CRISPR Cas9 patents and the differentiation of using Cas12a nuclease, which might have greater selectivity and efficiency over Cas9a CRISPR candidates. Read the full article on Seeking Alpha
分析記事 • Dec 15

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • May 10

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Celebrations may be in order for Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders, with the analysts delivering a...

CEO報酬分析

Editas Medicine の収益と比較して、Gilmore O’Neill の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$109m

Dec 31 2025US$2mUS$687k

-US$160m

Sep 30 2025n/an/a

-US$200m

Jun 30 2025n/an/a

-US$237m

Mar 31 2025n/an/a

-US$251m

Dec 31 2024US$5mUS$667k

-US$237m

Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

報酬と市場: Gilmoreの 総報酬 ($USD 2.35M ) は、 US市場 ($USD 1.74M ) の同規模の企業の平均を上回っています。

報酬と収益: Gilmoreの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Gilmore O’Neill (61 yo)

3.9yrs
在職期間
US$2,353,655
報酬

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Gilmore O’Neill
President3.9yrsUS$2.35m0.17%
$ 403.9k
Amy Parison
Senior VP & CFO1.2yrsUS$821.66k0.0073%
$ 17.7k
Linda Burkly
Executive VP & Chief Scientific Officer2.8yrsUS$1.18m0.029%
$ 70.8k
Feng Zhang
Co-Founder & Scientific Advisory Board Member13.3yrsデータなしデータなし
George Church
Co-Founder & Scientific Advisory Board Member13.3yrsデータなしデータなし
Gregory Whitehead
Executive VP and Chief Technical & Quality Officer2.1yrsデータなしデータなし
Damien Grierson
Senior VP1.3yrsデータなしデータなし
Tom Love
Vice President of Peopleless than a yearデータなしデータなし
Frank Panaccio
Senior VP & Chief Business Officer1.3yrsデータなしデータなし
Brieana Buckley
Senior Vice President of Development and Program Leadership1.3yrsデータなしデータなし
1.7yrs
平均在職期間
64.5yo
平均年齢

経験豊富な経営陣: EDITの経営陣は 経験豊富 とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Gilmore O’Neill
Presidentno dataUS$2.35m0.17%
$ 403.9k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno dataデータなしデータなし
George Church
Co-Founder & Scientific Advisory Board Memberno dataデータなしデータなし
Andrew Hirsch
Independent Director9yrsUS$118.71k0.0020%
$ 4.9k
Jessica Hopfield
Independent Chairman8.3yrsUS$146.21k0.069%
$ 166.5k
Elliott Levy
Independent Director3.1yrsUS$101.21k0%
$ 0
David Scadden
Independent Director7.3yrsUS$99.96k0%
$ 0
Bernadette Connaughton
Independent Director4.6yrsUS$112.46k0%
$ 0
7.3yrs
平均在職期間
67yo
平均年齢

経験豊富なボード: EDITの 取締役会 は 経験豊富 であると考えられます ( 7.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/20 15:47
終値2026/05/20 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Editas Medicine, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25

アナリスト機関
Jack AllenBaird
Joel BeattyBaird
Alec StranahanBofA Global Research